Buy (150 RUB)
Generate QR code
Open Access
Subscription or Fee Access
Current opportunities for prevention of chronic kidney disease progression in children
https://doi.org/10.21508/1027-4065-2022-67-2-20-27
Abstract
Chronic kidney disease is an urgent problem of childhood getting more and more interest on the one hand due to the higher incidence among children and the increased public health expenditures, and on the other hand due to the expanding opportunities for early diagnosis and prevention of the progression of this condition. Renoprotection means a set of measures of accompanying therapy that helps to preserve renal function, and in the case of advanced chronic renal failure — to maintain their residual function. The renoprotective strategy in children differs from that in adults, which is associated with the peculiarity of the causes of chronic kidney disease and the age-related characteristics of the physiology and pathology of body systems.
About the Authors
V. A. Polkanova
Samara State Medical University
Russian Federation
Russian Federation
Samara
E. N. Voronina
Samara State Medical University
Russian Federation
Russian Federation
Samara
D. V. Pechkurov
Samara State Medical University
Russian Federation
Russian Federation
Samara
References
1. Hill N.R., Fatoba S.T., Oke J.L., Samuel T., Oke J.L., Hirst J.A. et al. Global Prevalence of Chronic Kidney Disease — Systematic Review and Meta-analysis. PLoS One 2016; 11(7): e0158765. DOI: 10,1371/journal.pone.0158765
2. Hogg R.J., Furth S., Lemley K.V., Portman R., Schwartz G.J., Coresh J. et al. National Kidney Foundation’s Kidney Disease Outcomes Quality Initiative clinical practice guidelines for chronic kidney disease in children and’ adolescents: evaluation, classification and stratification. Pediatrics 2003; 3(6): 1416–1421
3. North American Pediatric Renal Transplant Cooperative Study (NARPTCS) 2008 Annual report. The EMMES Corporation, Rockville, MD. https://www.nejm.org/doi/full/10,1056/NEJM199206253262602. Ссылка активна на 15.01.2021.
4. Weaver D.J., Somers M.J.G., Martz K., Mitsnefes M.M. Clinical outcomes and survival in pediatric patients initiating chronic dialysis: a report of the NAPRTCS registry. Pediatr Nephrol 2017; 32(12): 2319–2330. DOI: 10,1007/s00467–017–3759–4
5. Lysova E.V. The etiological structure of chronic kidney disease in children and adolescents. Pediatriya 2016; 7(2): 204–205. (in Russ.)
6. Lysova E.V., Savenkova N.D. CAKUT-syndrome in the etiological structure of chronic kidney disease in children and adolescents, Nefrologiya 2017; 21(3): 69–74. (in Russ.)
7. Zorin I.V., Vyalkova A.A. Prevention of the progression of chronic kidney disease in children with reflux nephropathy. Lechashhii vrach 2015; 1: 59. (in Russ.)
8. Tomilina N.A., Andrusev A.M., Peregudova N.G., Shinkareva M.B. Substitution therapy of terminal chronic renal failure in the Russian Federation in 2010–2015. Report on the data of the All-Russian Register of Renal Substitution Therapy of the Russian Dialysis Society. Part one. Nefrologiya i Dializ 2017; 4(19): 1–95. (in Russ.)
9. National recommendations. Chronic kidney disease: basic principles of screening, diagnosis, prevention and treatment approaches. Nefrologiya 2012; 16(1): 89–115. (in Russ.)
10. Ignatova M.S. Prevention of the development and progression of chronic kidney disease in children. Rossiyskiy vestnik perinatologii i pediatrii 2009; 54(5): 6–13. (in Russ.)
11. Vyalkova A.A., Zorin I.V., Chesnokova S.A., Plotnikova S.V. Early diagnosis of chronic kidney disease in children. Nefrologiya 2019; 23(6): 135–136. (in Russ.)
12. Komarova O.V., Kucherenko A.G., Smirnov I.E., Tsygin A.N. The role of apoptosis in the progression of chronic kidney disease in children. Nefrologiya i dializ 2013; 15(4): 375. (in Russ.)
13. Krasnov M.V., Makarova T.A., Krasnov V.M. Modern concepts of kidney disease in children and the principles of therapy. In the collection: Actual problems of pediatric uronephrology. Materials of the Interregional Scientific and Practical Conference dedicated to the 230th anniversary of the birth of the founder of nephrology, Richard Bright. Chuvash State University named after I.N. Ulyanova, Chuvash regional branch of the Union of Pediatricians of Russia. 2019: 26–44. (in Russ.)
14. Otroshchenko E.S., Leonova L.V., Komarova O.V., Timofeeva A.G., Tsygin A.N. The effectiveness of the combined pharmacological blockade of the renin-angiotensin-aldosterone system in children with chronic kidney disease. Pediatricheskaya farmakologiya 2010; 7(2): 105–109. (in Russ.)
15. Nastausheva T.L., Zhdanova O.A., Nastausheva N.S., Minakova O.V., Zvyagina T.G., Stakhurlova L.I. et al. Physical development of children with chronic kidney disease caused by recurrent pyelonephritis. Voprosy` prakticheskoi pediatrii 2016; 11(3): 14–21. (in Russ.)
16. Fried L.F., Emanuele N., Zhang J.H., Brophy M., Conner T.A., Duckworth W. et al.; VA NEPHRON-D Investigators. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013; 369(20): 1892–1903. DOI: 10,1056/NEJMoa1303154
17. Mann J.F., Schmieder R.E., McQueen M., Dyal L., Schumacher H., Pogue J. et al; ONTARGET investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372(9638): 547–553. DOI: 10,1016/S0140–6736(08)61236–2. PMID: 18707986
18. Kohan D.E., Barton M. Endothelin and endothelin antagonists in chronic kidney disease. Kidney Int 2014; 86(5): 896– 904. DOI: 10,1038/ki.2014,143
19. Vilayur E., Harris D.C. Emerging therapies for chronic kidney disease: what is their role? Nat Rev Nephrol 2009; 5(7): 375–383. DOI: 10,1038/nrneph.2009,76.
20. Aksenova M.E. Pathology of the cardiovascular system in children with chronic kidney disease: epidemiology, risk factors, pathogenesis. Rossiyskiy vestnik perinatologii i pediatrii 2015; 60(2): 22–28. (in Russ.)
21. Nephrology: national guidelines edited by O.N. Mukhina. M.: GEOTAR-Media, 2009; 720. (in Russ.)
22. Pediatric Nephrology. Editors Avner E.D., Harmon W.E., Niaudet P. Philadelphia: Lippincott Williams & Wilkins, 2004; 1564
23. Pediatric nephrology. Editors Rees L., Webb N., Brogan P. London: Oxford University Press, 2007; 618
24. Makovetskaya G.A., Mazur L.I., Terekhin S.S. Chronic kidney disease in children with congenital obstructive uropathy: prevention of progression. Samara: As Gard, 2014; 154. (in Russ.)
25. Aborin S.V. Acute kidney injury in premature infants: clinical significance, mechanism of development, early diagnosis. Aspirantskii vestnik Povolzh`ya 2016; 1(2): 44–50. (in Russ.)
26. Chichuga E.M., Nastausheva T.L., Zvyagina T.G. Markers of chronic kidney disease in children with urinary tract obstruction or vesicoureteral reflux. Pediatricheskaya farmakologiya 2015; 12(4): 407–413. (in Russ.)
27. Kolbe O.B., Moiseev A.B., Trufanova A.V., Zubavina M.N., Badyaeva S.A. et al. Possibilities of Doppler study of renal vessels for optimization of nephroprotective therapy in children with renal anomalies and corrected obstructive uropathies. Pediatriya. Zhurnal im. G.N. Speranskogo 2011; 90(3): 29–34. (in Russ.)
28. Lysova E.V., Savenkova N.D. Treatment of anemia syndrome in children with chronic kidney disease. Nefrologiya 2015; 19(3): 20–31. (in Russ.)
29. Avram M.M. An introduction and overview to new therapeutic approaches to the management of renal disease. Kidney Int 2006; 70: 1–3
30. Neuen B.L., Jardine M.J., Perkovic V. Sodium-glucose cotransporter 2 inhibition: which patient with chronic kidney disease should be treated in the future? Nephrol Dial Transplant 2020; 35(Suppl 1): i48–i55. DOI: 10,1093/ndt/gfz252
31. Zhong J., Yang H.C., Fogo A.B. A perspective on chronic kidney disease progression. Am J Physiol Renal Physiol 2017; 312(3): F375–F384. DOI: 10,1152/ajprenal.00266,2016
32. Chin M.P., Bakris G.L., Block G.A., Chertow G.M., Goldsberry A., Inker L.A. et al. Bardoxolone Methyl Improves Kidney Function in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes Study. Am J Nephrol 2018; 47(1): 40– 47. DOI: 10,1159/000486398
33. Shavlokhova E.A., Kharebova F.Yu. Ramipril in patients with diabetic nephroprotection. In the book: Arterial hypertension 2017 as an interdisciplinary problem. Collection of abstracts of the XIII All-Russian Congress. OOO "InterMedservis". Moskva. 2017; 83–84 (in Russ.)
34. Ivanov D.D. Diuretics and new possibilities in nephroprotection. Pochki 2019; 8(1): 2–6. (in Russ.)
35. Filipets N.D., Ivanov D.D., Gozhenko A.I. Blockers of the renin-angiotensin-aldosterone system as the main pathogenetic direction of drug nephroprotection. Pochki 2019; 8(1): 34–39. (in Russ.)
36. Flynn J.T., Kaelber D.C., Baker-Smith C.M. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics 2017; 140: 61–75. DOI: 10,1542/peds.2017–1904
37. Gallibois C., Jawa N., Noone D. Hypertension in pediatric patients with chronic kidney disease: management challenges. Int J Nephrol Renovasc Dis 2017; 10: 205–222. DOI: 10,2147/IJNRD.S100891
38. Mambetova A.M. Inarokova A.M., Shabalova N.N., Bizheva D.V. Evaluation of the effect of nephroprotective therapy with angiotensin-converting enzyme inhibitors on the course of chronic kidney disease in children with congenital malformations of the urinary system. Nefrologiya 2019; 23(3): 59–64. (in Russ.)
39. Makovetskaya G.A., Mazur L.I., Balashova E.A., Terekhin S.S. Congenital obstructive uropathy in children: nephroprotective strategy. Pediatriya. Zhurnal im. G.N. Speranskogo 2017; 96(5): 38–43. (in Russ.)
40. Prikhodina L.S., Zakharova I.N. Progression of kidney disease in children: pathogenesis, risk factors, therapy. Moscow: RMANPO, 2019:77. (in Russ.)
41. Barinov I.V., Makovetskaya G.A., Borisova O.V., Mazur L.I. Clinical and immunological parallels in chronic renal failure in children. Allergologiya i immunologija v pediatrii 2020; 2(61): 41–48. (in Russ.)
42. Barinov I.V., Borisova O.V. Prediction of the formation of chronic kidney disease in children with acute kidney injury. Prakticheskaya meditsina 2020; 18(3): 70–75. (in Russ.)
43. Vakulenko L.I. The effectiveness of nephroprotective therapy in children with chronic pyelonephritis in follow-up observation. Zdorov`e rebenka 2018; 13(2): 165–170. (in Russ.)
44. Sergeeva T.V., Voznesenskaya T.S., Kartamysheva N.N., Borovik T.E., Kutafina E.K., Semenova N.N. et al. Diet therapy for chronic kidney disease in children. Rossiyskiy pediatricheskiy zhurnal 2014; 17(6): 23–27. (in Russ.)
45. Smirnova N.N., Sergeeva K.M. Metabolic syndrome and chronic kidney disease in children and adolescents. Profilakticheskaya i klinicheskaya meditsina 2011; 3(40): 185–191. (in Russ.)
46. Aparicio M., Cano N.J.M., Cupisti A., Ecder T., Fouque D., Garneata L. et al. KetoAcid Therapy in Predialysis Chronic Kidney Disease Patients: Consensus Statements. J Ren Nutr 2009; 19(5): 33–35. DOI: 10,1053/j.jrn.2011.09.006
47. Giovannetti S., Maggiore Q. A low-nitrogen diet with protein of high biological value for severe chronic uraemia. Lancet 1964; 37: 1000(3): 91–119
48. Zavyalova A.N., Gostimsky A.V., Fedorets V.N. Dietary approaches to the management of children with chronic kidney disease. Prakticheskaya meditsina 2019; 17(5): 152–160. (in Russ.)
49. Chauveau P., Couzi L., Vendrely B., de Précigout V., Combe C., Fouque D., Aparicio M. Long-term outcome on renal replacement therapy in patients who previously received a keto acid-supplemented Very-low-protein diet. Am J Clin Nutr 2009; 90(4): 969–974. DOI: 10,3945/ajcn.2009,27980
50. Mukhin N.A., Kozlovskaya L.V., Fomin V.V., Milovanov Yu.S. MDRD Research: Implications for Clinical Nephrology. Klinicheskaya nefrologiya 2013; 4: 4–7. (in Russ.)
51. Sigitova O.N., Arkhipov E.V., Kim T.Yu. Analysis of the effectiveness of nephroprotection using a low protein diet and keto analogs of amino acids in patients with chronic kidney disease. Kardiologiya 2015; 55(9): 43–49. (in Russ.)
52. Fomina S., Bagdasarova I. Protein restriction in the diet of children with stage 3–4 chronic kidney disease. Ukrains`ki j zhurnal nefrologii ta dializu 2013; 3: 84–89. (in Russ.)
53. Kushnirenko S.V., Ivanov D.D. Experience of using essential amino acids and their keto analogs in children with chronic kidney disease. Pochki 2013; 1(3): 35–38. (in Russ.)
54. Petrosyan E.K., M.S. Molchanova. Chronic kidney disease. Pediatric nephrology. Editors Shumilova V.P., Petrosyan E.K., Chugunova O.L. M: MEDpress-inform, 2018; 616. (in Russ.)
55. Cianciaruso B., Pota A., Bellizzi V., Di Giuseppe D., Di Micco L., Minutolo R. et al. Effect of a Low Versus Moderate-Protein Diet on Progression of CKD: Follow-up of a Randomized Controlled Trial. Am J Kidney Dis 2009; 54(5): 1052–1061. DOI: 10,1053/j.ajkd.2009.07.021
56. Shaikhova G.I., Otazhonov I.O., Rustamova M.T. Low-protein diet for patients with chronic kidney disease. E`ksperimental`naya i klinicheskaya gastroe`nterologiya 2019; 12(172): 135–142. (in Russ.)
57. Zavyalova A.N., Gostimsky A.V., Fedorets V.N. Possibilities of diet therapy in correcting the nutritional status of children with chronic kidney disease (literature review). Meditsina: teoriya i praktika 2020; 5(1): 50–61. (in Russ.)
58. Kramer H. Diet and Chronic Kidney Disease. Adv Nutr 2019; 1: 10(4): 367–379. DOI: 10,1093/advances/nmz011
59. Rysz J., Franczyk B., Ciałkowska-Rysz A., Gluba-Brzózka A. The Effect of Diet on the Survival of Patients with Chronic Kidney Disease. Nutrients 2017; 9(5): 495. DOI: 10,3390/nu9050495
Review
For citations:
Polkanova V.A., Voronina E.N., Pechkurov D.V. Current opportunities for prevention of chronic kidney disease progression in children. Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics). 2022;67(2):20-27. (In Russ.) https://doi.org/10.21508/1027-4065-2022-67-2-20-27
Views:
649
Email this article 